

Vivimed Labs Limited

October 16, 2025

| Facilities/Instruments | Amount (₹ crore) | Rating ¹ | Rating Action |
|----------------------------|---------------------|---------------------------------|--|
| Long Term Bank Facilities | 266.93 | CARE D; ISSUER NOT COOPERATING* | Rating continues to remain under ISSUER NOT COOPERATING category |
| Short Term Bank Facilities | 109.50 | CARE D; ISSUER NOT COOPERATING* | Rating continues to remain under ISSUER NOT COOPERATING category |

Details of instruments/facilities in Annexure-1.

*Issuer did not cooperate; based on best available information.

Rationale and key rating drivers

CARE had, vide its press release dated July 23, 2024, placed the rating(s) of Vivimed Labs Limited (VLL) under the 'issuer non-cooperating' category as VLL had failed to provide information for monitoring of the rating. VLL continues to be non-cooperative despite repeated requests for submission of information through e-mails, phone calls and an email dated June 08, 2025 to October 10, 2025. In line with the extant SEBI guidelines, CARE has reviewed the rating based on the best available information which however, in CARE Rating's opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders, and the public at large) are hence requested to exercise caution while using the above rating(s).

The reaffirmation in the ratings assigned to the bank facilities of Vivimed Labs Limited (VLL) is primarily due to continued delays in the company's ability to meet debt obligations due to cash flow mismatches and deterioration in the liquidity profile.

Analytical approach: Consolidated; CARE has considered the consolidated financials and business profile of VLL and its subsidiaries. List of subsidiaries mentioned as Annexure – 6.

Outlook: Not applicable

Detailed description of key rating drivers

At the time of last rating on July 23, 2024 the following were the rating strengths and weaknesses

Key weaknesses

Cash flow mismatches and stretched liquidity resulting in ongoing delays in debt servicing

The liquidity profile of VLL deteriorated on account of cash flow mismatches. The same has resulted in delays with respect to debt servicing of the company.

Decline in financial performance

The financial profile of the company continued to deteriorate in FY25 with continued losses. The TOI of company declined from Rs. 136.79 crore in FY24 to Rs. 103.64 crore in FY25.

Key strengths

Experienced & qualified promoters and management team

The promoters of VLL have over two decades of experience in the pharmaceutical and chemical business. Mr. Santosh Varalwar (Managing Director), a management graduate, is primarily responsible for developing new markets for the company's products. VLL's board is ably supported by a team of professionals in the areas of finance, marketing, quality control, R&D, material and production.

¹Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited's publications.

Long-track record of operations with a unique diversified product portfolio backed by marquee clientele

VLL, established in 1988, is a global player engaged in manufacturing of speciality chemicals and pharmaceutical products. The company has 12 manufacturing facilities and 6 R&D facilities spread across the globe

Liquidity: Not available

Assumptions/Covenants: Not applicable

Environment, social, and governance (ESG) risks: Not applicable

Applicable criteria

[Definition of Default](#)

[Information Adequacy Risk and Issuer Non-Cooperation](#)

[Rating Outlook and Rating Watch](#)

[Liquidity Analysis of Non-Financial Sector Entities](#)

[Consolidation](#)

[Manufacturing Companies](#)

[Pharmaceuticals](#)

[Financial Ratios – Non financial Sector](#)

[Short Term Instruments](#)

[Factoring Linkages - Parent Sub JV Group](#)

About the company and industry

Industry classification

| Macroeconomic indicator | Sector | Industry | Basic industry |
|-------------------------|------------|---------------------------------|-----------------|
| Healthcare | Healthcare | Pharmaceuticals & Biotechnology | Pharmaceuticals |

Vivimed Labs Limited (VLL) incorporated in 1988 is a Hyderabad-based listed company engaged in manufacturing of pharmaceuticals (APIs and formulations for various therapeutic segments), personal care and colour chemistry industrial products. VLL has manufacturing facilities in India and Overseas (under subsidiaries). Within the FDF business, it provides contract manufacturing services to some of its marquee clients in the pharmaceuticals space, namely Novartis International AG, Glenmark Pharmaceuticals, Lupin, GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharmaceuticals), Dr. Reddy's Laboratories, Cipla, Abbott Laboratories, Merck Serono, Wockhardt, and so on. VLL has 12 manufacturing facilities, 6 R&D centres and global support offices in India, China, Europe and the US which adhere to the highest levels of compliance and manufacture high-quality products.

| Brief Financials (₹ crore) – Consolidated | March 31, 2024 (A) | March 31, 2025 (A) | Q1FY26 (UA) |
|--|--------------------|--------------------|-------------|
| Total operating income | 149.07 | 116.28 | 21.39 |
| PBILDT | -5.96 | -13.01 | -0.28 |
| PAT | -45.45 | -31.96 | -5.49 |
| Overall gearing (times) | -1.91 | -1.66 | NA |
| Interest coverage (times) | -2.00 | -4.36 | NA |

A: Audited UA: Unaudited NA: Not Available; Note: these are latest available financial results

| Brief Financials (₹ crore) - Standalone | March 31, 2024 (A) | March 31, 2025 (A) | Q1FY26 (UA) |
|---|--------------------|--------------------|-------------|
| Total operating income | 136.86 | 103.61 | 17.94 |
| PBILDT | -6.16 | -14.50 | -0.54 |
| PAT | -44.38 | -31.50 | -5.60 |
| Overall gearing (times) | -21.70 | -7.99 | NA |
| Interest coverage (times) | -2.55 | -5.71 | NA |

A: Audited UA: Unaudited NA: Not Available; Note: these are latest available financial results

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

| Name of the Instrument | ISIN | Date of Issuance (DD-MM-YYYY) | Coupon Rate (%) | Maturity Date (DD-MM-YYYY) | Size of the Issue (₹ crore) | Rating Assigned and Rating Outlook |
|--|------|-------------------------------|-----------------|----------------------------|-----------------------------|------------------------------------|
| Fund-based - LT-Cash Credit | | - | - | - | 152.00 | CARE D; ISSUER NOT COOPERATING* |
| Fund-based - LT-External Commercial Borrowings | | - | - | March 2019 | 32.50 | CARE D; ISSUER NOT COOPERATING* |
| Fund-based - LT-Term Loan | | - | - | July 2021 | 82.43 | CARE D; ISSUER NOT COOPERATING* |
| Fund-based - ST-Bill Discounting/ Bills Purchasing | | - | - | - | 30.00 | CARE D; ISSUER NOT COOPERATING* |
| Fund-based - ST-EPC/PSC | | - | - | - | 32.50 | CARE D; ISSUER NOT COOPERATING* |
| Non-fund-based - ST-Bank Guarantee | | - | - | - | 1.00 | CARE D; ISSUER NOT COOPERATING* |
| Non-fund-based - ST-Letter of credit | | - | - | - | 46.00 | CARE D; ISSUER NOT COOPERATING* |

*Issuer did not cooperate; based on best available information.

Annexure-2: Rating history for last three years

| Sr. No. | Name of the Instrument/Bank Facilities | Current Ratings | | | Rating History | | | |
|---------|--|-----------------|------------------------------|---------------------------------|---|---|---|---|
| | | Type | Amount Outstanding (₹ crore) | Rating | Date(s) and Rating(s) assigned in 2025-2026 | Date(s) and Rating(s) assigned in 2024-2025 | Date(s) and Rating(s) assigned in 2023-2024 | Date(s) and Rating(s) assigned in 2022-2023 |
| 1 | Fund-based - LT-Cash Credit | LT | 152.00 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING* (23-Jul-24) | 1)CARE D; ISSUER NOT COOPERATING* (19-Jun-23) | 1)CARE D; ISSUER NOT COOPERATING* (31-May-22) |
| 2 | Non-fund-based - ST-Letter of credit | ST | 46.00 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING* (23-Jul-24) | 1)CARE D; ISSUER NOT COOPERATING* (19-Jun-23) | 1)CARE D; ISSUER NOT COOPERATING* (31-May-22) |
| 3 | Fund-based - LT-Term Loan | LT | 82.43 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING* (23-Jul-24) | 1)CARE D; ISSUER NOT COOPERATING* (19-Jun-23) | 1)CARE D; ISSUER NOT COOPERATING* (31-May-22) |
| 4 | Fund-based - ST-EPC/PSC | ST | 32.50 | CARE D; ISSUER NOT | - | 1)CARE D; ISSUER NOT | 1)CARE D; ISSUER NOT | 1)CARE D; ISSUER NOT |

| Sr. No. | Name of the Instrument/Bank Facilities | Current Ratings | | | Rating History | | | |
|---------|--|-----------------|------------------------------|---------------------------------|---|---|---|---|
| | | Type | Amount Outstanding (₹ crore) | Rating | Date(s) and Rating(s) assigned in 2025-2026 | Date(s) and Rating(s) assigned in 2024-2025 | Date(s) and Rating(s) assigned in 2023-2024 | Date(s) and Rating(s) assigned in 2022-2023 |
| | | | | COOPERATING* | | COOPERATING* (23-Jul-24) | COOPERATING* (19-Jun-23) | COOPERATING* (31-May-22) |
| 5 | Fund-based - ST-Bill Discounting/ Bills Purchasing | ST | 30.00 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING* (23-Jul-24) | 1)CARE D; ISSUER NOT COOPERATING* (19-Jun-23) | 1)CARE D; ISSUER NOT COOPERATING* (31-May-22) |
| 6 | Non-fund-based - ST-Bank Guarantee | ST | 1.00 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING* (23-Jul-24) | 1)CARE D; ISSUER NOT COOPERATING* (19-Jun-23) | 1)CARE D; ISSUER NOT COOPERATING* (31-May-22) |
| 7 | Fund-based - LT-External Commercial Borrowings | LT | 32.50 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING* (23-Jul-24) | 1)CARE D; ISSUER NOT COOPERATING* (19-Jun-23) | 1)CARE D; ISSUER NOT COOPERATING* (31-May-22) |

*Issuer did not cooperate; based on best available information.

LT: Long term; ST: Short term; LT/ST: Long term/Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not applicable

Annexure-4: Complexity level of instruments rated

| Sr. No. | Name of the Instrument | Complexity Level |
|---------|--|------------------|
| 1 | Fund-based - LT-Cash Credit | Simple |
| 2 | Fund-based - LT-External Commercial Borrowings | Simple |
| 3 | Fund-based - LT-Term Loan | Simple |
| 4 | Fund-based - ST-Bill Discounting/ Bills Purchasing | Simple |
| 5 | Fund-based - ST-EPC/PSC | Simple |
| 6 | Non-fund-based - ST-Bank Guarantee | Simple |
| 7 | Non-fund-based - ST-Letter of credit | Simple |

Annexure-5: Lender details

To view lender-wise details of bank facilities please [click here](#)

Annexure-6: List of entities consolidated

| Sr No | Name of the entity | Extent of consolidation | Rationale for consolidation |
|-------|--------------------------------|-------------------------|-----------------------------|
| 1 | Finoso Pharma Private Limited | Full | Wholly owned subsidiary |
| 2 | Vivimed Holdings Limited | Full | Wholly owned subsidiary |
| 3 | Vivimed Labs USA Inc | Full | Wholly owned subsidiary |
| 4 | Vivimed Labs Mauritius Limited | Full | Wholly owned subsidiary |

Note on complexity levels of rated instruments: CareEdge Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

Contact us

| | |
|---|--|
| Media Contact Mradul Mishra Director CARE Ratings Limited Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in Relationship Contact Saikat Roy Senior Director CARE Ratings Limited Phone: 912267543404 E-mail: saikat.roy@careedge.in | Analytical Contacts Karthik Raj K Director CARE Ratings Limited Phone: +91-80-4662 6666 E-mail: karthik.raj@careedge.in Y Tejeshwar Reddy Associate Director CARE Ratings Limited Phone: +91-40-4010 2030 E-mail: Tejeshwar.Reddy@careedge.in Saba Shaikh Lead Analyst CARE Ratings Limited E-mail: Saba.Shaikh@careedge.in |
|---|--|

About us:

Established in 1993, CareEdge Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the Reserve Bank of India. With an equitable position in the Indian capital market, CareEdge Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CareEdge Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CareEdge Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit. For more information: www.careratings.com

Disclaimer:

This disclaimer pertains to the ratings issued and content published by CARE Ratings Limited ("CareEdge Ratings"). Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. Any opinions expressed herein are in good faith and are subject to change without notice. The rating reflects the opinions as on the date of the rating. A rating does not convey suitability or price for the investor. The rating agency does not conduct an audit on the rated entity or an independent verification of any information it receives and/or relies on for the rating exercise. CareEdge Ratings has based its ratings/outlook on the information obtained from reliable and credible sources. CareEdge Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. The users of the rating should rely on their own judgment and may take professional advice while using the rating in any way. CareEdge Ratings shall not be liable for any losses that user may incur or any financial liability whatsoever to the user of the rating. The use or access of the rating does not create a client relationship between CareEdge Ratings and the user.

CAREEDGE RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, TO THE EXTENT PERMITTED BY APPLICABLE LAWS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE.

Most entities whose bank facilities/instruments are rated by CareEdge Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CareEdge Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. CareEdge Ratings does not act as a fiduciary by providing the rating. The ratings are intended for use only within the jurisdiction of India. The ratings of CareEdge Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades. CareEdge Ratings has established policies and procedures as required under applicable laws and regulations which are available on its website.

Privacy Policy applies. For Privacy Policy please refer to https://www.careratings.com/privacy_policy

© 2025, CARE Ratings Limited. All Rights Reserved.

This content is being published for the purpose of dissemination of information. Any use or reference to the contents herein on an "as-is" basis is permitted with due acknowledgement to CARE Ratings. Reproduction or retransmission in whole or in part is prohibited except with prior written consent from CARE Ratings.

For detailed Rating Report and subscription information, please visit www.careratings.com